A Phase 3 interventional study of Retatrutide and Placebo in Obesity, Overweight and Chronic Low Back Pain (CLBP), sponsored by Eli Lilly and Company. Active, not recruiting at 40 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
The main purpose of this study is to evaluate the efficacy and safety of retatrutide in relieving chronic low back pain in participants who have obesity or overweight. Participation in the study will last about 80 weeks.
6,296 studies on the registry are indexed under Obesity; 1,692 are open to participants now.
This study's planned enrollment of 586 is above the median of 78 across 4,878 interventional studies indexed under Obesity.
Browse Obesity studies →Eli Lilly and Company is the lead sponsor of 2,048 studies on the registry; 140 are open to participants now.
Of its 521 completed or terminated interventional studies of FDA-regulated products, 341 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Participants will receive Retatrutide subcutaneously (SC)
Drug: Retatrutide
Participants will receive Placebo SC
Drug: Placebo
Administered SC
Also known as: LY3437943
Administered SC
Change from Baseline in Pain Intensity Per Numeric Rating Scale
Time frame: Baseline, up to 72 weeks
Percent Change from Baseline in Body Weight
Time frame: Baseline, up to 72 weeks
Number of Participants with Reduction in Pain Intensity Per Numeric Rating Scale
Time frame: Baseline, up to 72 weeks
Number of Participants with Reduction in Body Weight
Time frame: Baseline, up to 72 weeks
Change in Physical Function as Measured by Patient-Reported Outcomes Measurement Information Systems (PROMIS)
Time frame: Baseline, up to 72 weeks
Change in Pain Interference as Measured by PROMIS
Time frame: Baseline, up to 72 weeks
Change in Sleep as Measured by PROMIS
Time frame: Baseline, up to 72 weeks
Change in Patient Reported Health Outcomes as Measured by Medical Outcomes Study 36-item Short Form Health Survey version 2 (SF-36v2)
Time frame: Baseline, up to 72 weeks
Change in Waist Circumference
Time frame: Baseline, up to 72 weeks
Change in Biomarkers of Inflammation as Measured by Blood Test
Time frame: Baseline, up to 72 weeks
Change in Blood Pressure
Time frame: Baseline, up to 72 weeks
Change in Glycemic Control
Time frame: Baseline, up to 72 weeks
Percent Change in Total Cholesterol
Time frame: Baseline, up to 72 weeks
Percent Change in Urine Albumin-to-Creatinine Ratio (UACR)
Time frame: Baseline, up to 72 weeks
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Sap, Csr
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Eli Lilly and Company